Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06361316
Status:
RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-03-25
Brief Title:
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Sponsor:
Kuirong Jiang
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur NASOX in Adjuvant Chemotherapy for Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur NASOX for postoperative adjuvant chemotherapy for pancreatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None